Patents by Inventor Randall T. Peterson
Randall T. Peterson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240287609Abstract: Disclosed herein are droplets comprising gene editing systems and barcodes. The disclosure further relates to methods for large-scale identification of genes in vivo using barcodes and methods for large-scale identification of gene function in a plurality of subjects using a plurality of droplets.Type: ApplicationFiled: June 8, 2022Publication date: August 29, 2024Inventors: Saba Parvez, Randall T. Peterson, Jing-Ruey Joanna Yeh
-
Patent number: 11396516Abstract: The present application provides tricyclic compounds useful, e.g., in treating or preventing cardiotoxicity and cardiomyopathy in patients undergoing cardiotoxic chemotherapy. Methods of making and using the tricyclic compounds to treat cancer are also described.Type: GrantFiled: June 15, 2018Date of Patent: July 26, 2022Assignee: The General Hospital CorporationInventors: Randall T. Peterson, Aarti Asnani, Yan Liu, Baohui Zheng, You Wang
-
Publication number: 20210163495Abstract: The present application provides tricyclic compounds useful, e.g., in treating or preventing cardiotoxicity and cardiomyopathy in patients undergoing cardiotoxic chemotherapy. Methods of making and using the tricyclic compounds to treat cancer are also described.Type: ApplicationFiled: June 15, 2018Publication date: June 3, 2021Inventors: Randall T. Peterson, Aarti Asnani, Yan Liu, Baohui Zheng, You Wang
-
Publication number: 20200312426Abstract: Embodiments of the present invention provide materials and methods for performing phenotype-based chemical screens. Embodiments disclosed herein pertain to the use of a battery of high-throughput zebrafish behavioral assays to generate behavioral profiles. In accordance with these embodiments, responses to various chemical compounds with known and unknown biological functions can be used to generate behavioral profiles. Embodiments also involve generating behavioral profiles based on genetic mutations or environmental perturbations. Establishing databases of behavioral profiles facilitates identification of novel chemicals that phenocopy effects of therapeutic agents and/or that modulate genetic or environmental behavioral profiles, thereby providing a basis for not only assessing the properties of known chemical compounds but also for developing novel treatments for human diseases.Type: ApplicationFiled: March 6, 2020Publication date: October 1, 2020Applicants: NemaMetrix, Inc, The General Hospital Corportation, dba Massachusetts General HospitalInventors: David Kokel, Randall T. Peterson, Giancarlo Bruni, Andrea Velenich
-
Publication number: 20190337956Abstract: The invention described herein relates generally to neuroactive compounds and compositions for the treatment psychotic disorders, methods for treating psychosis using these neuroactive compounds, and methods for screening for novel neuroactive compounds. Certain aspects are directed to a family of compounds called “finazines.” Certain aspects are directed to in vivo screening methods using high-throughput behavioral assays in zebrafish.Type: ApplicationFiled: April 9, 2019Publication date: November 7, 2019Applicant: The General Hospita CorporationInventors: Randall T. Peterson, Andrew J. Rennekamp, David Kokel, You Wang
-
Patent number: 10301318Abstract: The invention described herein relates generally to neuroactive compounds and compositions for the treatment psychotic disorders, methods for treating psychosis using these neuroactive compounds, and methods for screening for novel neuroactive compounds. Certain aspects are directed to a family of compounds called “finazines.” Certain aspects are directed to in vivo screening methods using high-through-put behavioral assays in zebrafish.Type: GrantFiled: June 25, 2015Date of Patent: May 28, 2019Assignee: The General Hospital CorporationInventors: Randall T. Peterson, Andrew J. Rennekamp, David Kokel, You Wang
-
Publication number: 20180161310Abstract: Compounds that inhibit synaptic hyperexcitability, pharmaceutical compositions of these compounds, and methods of using the compounds and pharmaceutical compositions thereof to treat diseases and/or disorders such as epilepsy, neuropathic pain, spinal cord injury spasticity, morphine-induced hyperalgesia, schizophrenia, and autism spectrum disorders are disclosed.Type: ApplicationFiled: December 7, 2017Publication date: June 14, 2018Inventors: Randall T. Peterson, David Kokel, Tama Evron, Andrea Velenich
-
Publication number: 20170247383Abstract: The invention described herein relates generally to neuroactive compounds and compositions for the treatment psychotic disorders, methods for treating psychosis using these neuroactive compounds, and methods for screening for novel neuroactive compounds. Certain aspects are directed to a family of compounds called “finazines.” Certain aspects are directed to in vivo screening methods using high-through-put behavioral assays in zebrafish.Type: ApplicationFiled: June 25, 2015Publication date: August 31, 2017Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Randall T. PETERSON, Andrew J. RENNEKAMP, David KOKEL, You WANG
-
Publication number: 20170169164Abstract: Embodiments of the present invention provide materials and methods for performing phenotype-based chemical screens. Embodiments disclosed herein pertain to the use of a battery of high-throughput zebrafish behavioral assays to generate behavioral profiles. In accordance with these embodiments, responses to various chemical compounds with known and unknown biological functions can be used to generate behavioral profiles. Embodiments also involve generating behavioral profiles based on genetic mutations or environmental perturbations. Establishing databases of behavioral profiles facilitates identification of novel chemicals that phenocopy effects of therapeutic agents and/or that modulate genetic or environmental behavioral profiles, thereby providing a basis for not only assessing the properties of known chemical compounds but also for developing novel treatments for human diseases.Type: ApplicationFiled: October 27, 2016Publication date: June 15, 2017Inventors: David Kokel, Randall T. Peterson, Giancarlo Bruni, Andrea Velenich
-
Publication number: 20170079252Abstract: Provided herein are methods of sterilizing fish by contacting an embryonic or juvenile fish with a compound of formula (I). In some embodiments, the compound is primordazine or a derivative thereof.Type: ApplicationFiled: December 1, 2016Publication date: March 23, 2017Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Randall T. Peterson, Peter J. Schlueter
-
Patent number: 9538734Abstract: Provided herein are methods of sterilizing fish by contacting an embryonic or juvenile fish with a compound of formula (I). In some embodiments, the compound is primordazine or a derivative thereof.Type: GrantFiled: March 12, 2014Date of Patent: January 10, 2017Assignee: THE GENERAL HOSPITAL CORPORATIONInventors: Randall T. Peterson, Peter J. Schlueter
-
Publication number: 20160115167Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.Type: ApplicationFiled: March 4, 2014Publication date: April 28, 2016Inventors: Paul B. Yu, Gregory D. Cuny, Agustin H. Mohedas, Kenneth D. Bloch, Randall T. Peterson
-
Publication number: 20150150843Abstract: The invention provides a method of reducing anthracycline-induced cardiotoxicity by administering a toxicity-reducing compound, such as a compound of Formulas (I), (II) or (III) or a combination thereof, and/or diphenyl urea (DPU), dexrazoxane (DEX), to a patient receiving an anthracycline. The invention also provides a method of identifying toxicity-reducing compounds.Type: ApplicationFiled: May 16, 2013Publication date: June 4, 2015Inventors: Randall T. Peterson, Yan Liu
-
Patent number: 9045484Abstract: The present invention provides pyridinyl-substituted pyrazolyl pyrimidine small molecule inhibitors of bone morphogenetic protein (BMP) signaling having the structure of formula (I), wherein variables A, B, E, F, X, Y, Z, Ar, L1, R4 and R15 are as defined in the specification. The compounds of the invention are useful in modulating cell growth, differentiation, proliferation, and apoptosis, and thus are useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.Type: GrantFiled: July 12, 2013Date of Patent: June 2, 2015Assignees: The Brigham and Women's Hospital, Inc., The General Hospital CorporationInventors: Paul B. Yu, Gregory D. Cuny, Kenneth D. Bloch, Randall T. Peterson, Charles C. Hong
-
Publication number: 20140261212Abstract: Provided herein are methods of sterilizing fish by contacting an embryonic or juvenile fish with a compound of formula (I). In some embodiments, the compound is primordazine or a derivative thereof.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Randall T. PETERSON, Peter J. SCHLUETER
-
Publication number: 20140011805Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.Type: ApplicationFiled: July 12, 2013Publication date: January 9, 2014Inventors: Paul B. Yu, Gregory D. Cuny, Kenneth D. Bloch, Randall T. Peterson, Charles C. Hong
-
Patent number: 8507501Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.Type: GrantFiled: March 13, 2009Date of Patent: August 13, 2013Assignees: The Brigham and Women's Hospital, Inc., The General Hospital CorporationInventors: Paul B. Yu, Gregory D. Cuny, Kenneth D. Bloch, Randall T. Peterson, Charles C. Hong
-
Publication number: 20110053930Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.Type: ApplicationFiled: March 13, 2009Publication date: March 3, 2011Applicants: The Brigham and Women's Hospital, Inc., The General Hospital CorporationInventors: Paul B. Yu, Gregory D. Cuny, Kenneth D. Bloch, Randall T. Peterson, Charles C. Hong
-
Publication number: 20100093760Abstract: The invention provides methods for identifying compounds that modulate cell signaling, as well as therapeutic methods that employ such compounds.Type: ApplicationFiled: September 12, 2007Publication date: April 15, 2010Applicant: The General Hospital CorporationInventors: Paul B. Yu, Charles C. Hong, Kenneth D. Bloch, Randall T. Peterson
-
Publication number: 20080199449Abstract: The invention includes methods and compositions for use in treating or preventing vascular disease or promoting vascular growth or development. The methods and compositions can be used, for example, in the treatment of diseases associated with ischemia, such as heart attack and stroke.Type: ApplicationFiled: August 11, 2006Publication date: August 21, 2008Applicant: The General Hospital CorporationInventors: Randall T. Peterson, Charles C. Hong